http://professional.cancerconsultant....aspx?id=41280
Pertuzumab (Omnitarg™) and Herceptin® (Trastuzumab) Effective for Metastatic HER2-Positive Breast Cancer
Researchers involved in an international study have reported that the combination of Omnitarg and Herceptin has significant activity in women with HER2-positive breast cancer who progressed on Herceptin alone. The details of this Phase II study were presented at the 2007 meeting of the San Antonio Breast Cancer Symposium (SABCS) in December.
1